UNITED KINGDOM –AstraZeneca’s Alexion will pay US$775 million to Roche’s subsidiary, Chugai Pharmaceutical to resolve all patent disputes related to the C5 inhibitor Ultomiris (ravulizumab), the two companies have said.…
Read MoreAstraZeneca’s unit Alexion to pay Chugai US$775M to settle patent dispute
